Liver-specific regulatory nucleic acid sequences

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12590129B2 covering liver-specific regulatory nucleic acid sequences including cis-regulatory elements, promoters, and other regulatory elements capable of enhancing liver-specific gene expression. The patent names Michael Roberts, Juan Manuel Iglesias, Jorge Omar Yanez-Cuna, Nicolle Kippen, Ross Fraser, and Katie Baker as inventors, with 22 claims. Applications include gene therapy, bioprocessing, and biotechnology.

View original document View source feed page

What changed

The USPTO granted patent US12590129B2 on March 31, 2026, covering liver-specific regulatory nucleic acid sequences (cis-regulatory elements, promoters, expression constructs, vectors, and cells) that enhance liver-specific gene expression. The patent application (17295208) was originally filed on November 19, 2019, and contains 22 claims. The technology is particularly suited for gene therapy applications, bioprocessing, and broader biotechnology uses.

Regulated entities and patent holders should review this grant for potential licensing opportunities or to assess freedom-to-operate for liver-targeted gene therapy programs. Companies developing gene therapy products should evaluate whether their technologies may infringe these liver-specific regulatory sequences. The patent does not impose compliance deadlines but creates enforceable exclusive rights in the disclosed technology.

Source document (simplified)

← USPTO Patent Grants

Liver-specific regulatory nucleic acid sequences

Grant US12590129B2 Kind: B2 Mar 31, 2026

Inventors

Michael Roberts, Juan Manuel Iglesias, Jorge Omar Yanez-Cuna, Nicolle Kippen, Ross Fraser, Katie Baker

Abstract

The present invention relates to regulatory nucleic acid sequences, in particular liver-specific cis-regulatory elements, cis-regulatory modules, promoters and other such nucleic acid sequences, that are capable of enhancing liver-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such liver-specific regulatory nucleic acid sequences, and to methods of their use. The liver-specific regulatory nucleic acid sequences are of particular utility for gene therapy applications, but also find utility in other areas such as bioprocessing and biotechnology.